An official website of the United States government
Government Funding Lapse Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.
The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.
Updates regarding government operating status and resumption of normal operations can be found at opm.gov.
A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors
Trial Status: active
The purpose of this study is to characterize the safety and tolerability of ALTA2618 in
adults with AKT1 E17K-mutant advanced solid tumors.
Inclusion Criteria
Histologically confirmed diagnosis of a solid tumor malignancy harboring AKT1 E17K mutation identified through molecular testing (NGS- or PCR-based) with a Clinical Laboratory Improvement Amendments-certified (or equivalent) diagnostic test.
Unresectable or metastatic disease
Progressed on, intolerant to, or declined prior standard-of-care therapy (including targeted therapy, if applicable) appropriate to tumor type and stage
Evaluable or measurable disease per RECIST v1.1
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Adequate organ function.
Exclusion Criteria
Prior treatment with PI3K and/or mTOR inhibitors
Patients known to have KRAS, NRAS, HRAS, or BRAF genomic alterations in their tumor
Known condition that prohibits ability to swallow or absorb an oral medication Other inclusion/exclusion criteria may apply.
Additional locations may be listed on ClinicalTrials.gov for NCT06533059.
